Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...
Denali Therapeutics price target lowered to $35 from $38 at B. Riley
B. Riley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $38 and keeps a Buy rating on the shares following the Q4 ...